550 Shares in IDEXX Laboratories, Inc. (NASDAQ:IDXX) Acquired by Oak Thistle LLC

Oak Thistle LLC acquired a new position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the first quarter, HoldingsChannel.com reports. The fund acquired 550 shares of the company’s stock, valued at approximately $297,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in IDXX. Norges Bank purchased a new position in shares of IDEXX Laboratories in the fourth quarter worth approximately $512,190,000. International Assets Investment Management LLC boosted its holdings in shares of IDEXX Laboratories by 51,631.3% in the fourth quarter. International Assets Investment Management LLC now owns 547,834 shares of the company’s stock worth $304,075,000 after buying an additional 546,775 shares during the last quarter. Capital Research Global Investors purchased a new position in shares of IDEXX Laboratories in the fourth quarter worth approximately $135,910,000. TD Asset Management Inc raised its stake in IDEXX Laboratories by 178.8% during the 4th quarter. TD Asset Management Inc now owns 260,008 shares of the company’s stock worth $144,317,000 after acquiring an additional 166,751 shares during the period. Finally, Point72 Asset Management L.P. bought a new stake in IDEXX Laboratories during the 4th quarter worth approximately $78,001,000. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Insiders Place Their Bets

In other IDEXX Laboratories news, Director Bruce L. Claflin sold 200 shares of the business’s stock in a transaction dated Friday, May 17th. The shares were sold at an average price of $540.80, for a total value of $108,160.00. Following the completion of the transaction, the director now directly owns 161 shares in the company, valued at $87,068.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 2.18% of the stock is currently owned by corporate insiders.

IDEXX Laboratories Trading Down 2.2 %

Shares of IDXX traded down $10.80 during trading hours on Monday, reaching $476.40. 429,302 shares of the company traded hands, compared to its average volume of 474,885. The firm has a market cap of $39.35 billion, a price-to-earnings ratio of 46.12, a PEG ratio of 3.97 and a beta of 1.32. IDEXX Laboratories, Inc. has a 12-month low of $372.50 and a 12-month high of $583.39. The company has a current ratio of 1.57, a quick ratio of 1.16 and a debt-to-equity ratio of 0.40. The stock’s fifty day moving average price is $501.58 and its 200 day moving average price is $526.59.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Wednesday, May 1st. The company reported $2.81 earnings per share for the quarter, beating the consensus estimate of $2.68 by $0.13. The firm had revenue of $964.10 million during the quarter, compared to the consensus estimate of $965.43 million. IDEXX Laboratories had a return on equity of 63.66% and a net margin of 23.26%. Sell-side analysts forecast that IDEXX Laboratories, Inc. will post 11.03 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have commented on IDXX. Stifel Nicolaus decreased their target price on shares of IDEXX Laboratories from $520.00 to $510.00 and set a “hold” rating on the stock in a research note on Monday, June 24th. StockNews.com upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Friday, June 14th. Barclays decreased their target price on shares of IDEXX Laboratories from $655.00 to $570.00 and set an “overweight” rating on the stock in a research note on Thursday, May 2nd. Morgan Stanley decreased their target price on shares of IDEXX Laboratories from $620.00 to $596.00 and set an “overweight” rating on the stock in a research note on Tuesday, May 14th. Finally, William Blair reiterated an “outperform” rating on shares of IDEXX Laboratories in a research report on Tuesday, April 9th. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $586.63.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.